Quantcast

Latest Amgen Stories

2014-02-19 08:34:21

BURNABY, BC, Feb. 19, 2014 /PRNewswire/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation protein engineering technology (HuTARG(TM)), today announced the extension of its research collaboration with Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS' HuTARG(TM) technology. Under the terms of the agreement, ITS is entitled to specific license payments and development milestones. About Innovative Targeting Solutions Inc. Founded in...

2014-02-11 12:25:31

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6mkhtx/biosimilars) has announced the addition of the "Biosimilars Market by Product & Application - Global Forecast to 2018" [http://www.researchandmarkets.com/research/6mkhtx/biosimilars ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global market is segmented on the basis of products, applications, and...

2014-02-05 08:28:16

THOUSAND OAKS, Calif., Feb. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma. "Talimogene laherparepvec has...

2014-01-30 16:26:43

RUTHERFORD-2 Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2) trial evaluating evolocumab in combination with statins and other lipid-lowering therapies in patients with heterozygous familial hypercholesterolemia (HeFH) met its co-primary...

2014-01-29 23:32:09

Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014 Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products. The importance of...

2014-01-28 16:26:04

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week...

2014-01-23 16:25:15

THOUSAND OAKS, Calif., Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2013 financial results on Tuesday, Jan. 28, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PST. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management...

2014-01-23 08:31:51

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial evaluating evolocumab in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the...

2014-01-15 08:29:25

Collaboration Brings Unique Expertise Together THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together...

2014-01-09 16:25:47

THOUSAND OAKS, Calif., Jan. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 32(nd) Annual J.P. Morgan Healthcare Conference at 9:30 a.m. Pacific Standard Time on Tuesday, Jan. 14, 2014, at the Westin St. Francis in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related